CD95 ligand expression on corneal epithelium and endothelium influences the fates of orthotopic and heterotopic corneal allografts in mice

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 6, 2004, Pages 1908-1915

  Osawa, Hideya ^a,b   Maruyama, Kazuichi ^a   Streilein, J Wayne ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; FAS LIGAND; LIGAND; FASL PROTEIN, MOUSE; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA EPITHELIUM; CORNEA STROMA; CORNEA TRANSPLANTATION; DELAYED HYPERSENSITIVITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HETEROTOPIC TRANSPLANTATION; INCIDENCE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SENSITIZATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; IMMUNOLOGY; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PHYSIOLOGY;

ANIMALS; ANTERIOR CHAMBER; CORNEAL TRANSPLANTATION; ENDOTHELIUM, CORNEAL; EPITHELIUM, CORNEAL; FAS LIGAND PROTEIN; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HYPERSENSITIVITY, DELAYED; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED MRL LPR; TRANSPLANTATION, HETEROTOPIC;

EID: 3042538427     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0512     Document Type: Article

References (28)

1. Niederkkorn JY. The immune privilege of corneal allografts. Transplantation. 1999;67:1503-1508.
2. Streilein JW. Immunobiology and immunopathology of corneal transplantation: immune responses and the eye. Chem Immunol. 1999;73:186-206.
3. Nagata S, Goldstein P. The Fas death factor. Science. 1995;267: 1449-1454.
4. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16:39-43.
5. Griffith T, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
6. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
7. Yamagami S, Kawashima H, Tsuru T, Gregerson D. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation. 1997;64:1107-1111.
8. Hori J, Joyce N, Streilein JW. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci. 2000;41;443-452.
9. Hori J, Joyce NC, Streilein JW. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest Ophthalmol Vis Sci. 2000;41:3032-3042.
10. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997;7:738-743.
11. Chen J-J, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998;282:1714-1717.
12. Sugita S, Taguchi C, Takase H, et al. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br J Ophthalmol. 2000;84:1130-1134.
13. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000;191:1209-1220.
14. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045-2050.
15. Yamada J, Streilein JW. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci. 1997;38:2833-2843.
16. Tanaka, K, Yamada J, Joyce N, Streilein JW. Immunobiology of xenogeneic cornea grafts in mouse eyes. I. Fate of xenogeneic cornea tissue grafts implanted in the anterior chamber of mouse eyes. Transplantation. 2000;69:610-616.
17. Tanaka K, Streilein JW. Immunobiology of xenogeneic cornea grafts in mouse eyes. II. Immunogenicity of xenogeneic cornea tissue grafts implanted in anterior chamber of mouse eyes. Transplantation. 2000;69:616-623.
18. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice: evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-703.
19. Hori J, Streilein JW. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci. 2001;42:720-726.
20. Hori J, Streilein JW. Survival in high risk eyes of epithelium-deprived orthotopic corneal allografts reconstituted in vitro with syngeneic epithelium. Invest Ophthalmol Vis Sci. 2003;44:658-664.
21. Zhang J, Ma B, Barshak-Rothstein A, Fine A. Characterization of a novel cis-element that regulates Fas ligand expression in corneal endothelial cells. J Biol Chem. 1999;274:26537-26542.
22. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci. 1991;32:2723-2728.
23. + T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci. 1999;40:2614-2521.
24. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol. 1999;73:72-89.
25. Kezuka T, Streilein JW. Evidence for multiple CD95-CD95 ligand interactions in anterior chamber associated immune deviation (ACAID) induced by soluble protein antigen. Immunology. 2000; 99:451-457.
26. Yamada J, Streilein JW. Fate of orthotopic corneal allografts in C57BL/6 mice. Transplant Immunol. 1998;6:161-168.
27. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999; 5:292-297.
28. Stuart PM, Pan F, Plambeck S, Fersuon TA. FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci. 2003;44:93-98.